A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Project: Research

Project Details

StatusActive
Effective start/end date20/09/2119/09/26

Keywords

  • treatment safety
  • treatment efficacy
  • Thrombocytopenia
  • phase 3 study
  • multicentre trial